One-third of adults with Major Depressive Disorder (MDD) have experienced persistent symptoms which do not respond to pharmacological treatment. Navigated repeated TMS (rTMS) has been approved by the U.S. FDA and several regulatory agencies around the world as a non-invasive treatment for Major Depressive Disorder. rTMS has been proven beneficial for treatment-resistant MDD patients who had not previously responded to any antidepressant medication. More recently, long-term gains have been observed in MDD patients receiving rTMS treatment followed by pharmacotherapy.

visor2 can assist in appropriately guiding TMS application to target cortical areas, ensuring reproducibility across all treatment sessions. The standard protocol needed for TMS treatment for patients with depression can be easily performed when the stimulator is accompanied by the user-friendly visor2 neuronavigation workflows. Precise coil position, rotation, tilt and orientation angles can be conveniently achieved with visor2.

Further Potential Areas of Application* for visor2 within Psychiatry

Attention Deficit Hyperactivity Disorder
Autism
Mania
Schizophrenia
Obsessive-Compulsive Disorder
Post traumatic Stress Disorder

* Under clinical investigation